114 related articles for article (PubMed ID: 22928441)
1. [Multiple endocrine neoplasia type 2 in Japan: large-scale analysis of data from the MEN consortium of Japan].
Uchino S
Nihon Geka Gakkai Zasshi; 2012 Jul; 113(4):362-7. PubMed ID: 22928441
[TBL] [Abstract][Full Text] [Related]
2. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
[TBL] [Abstract][Full Text] [Related]
3. [Multiple endocrine neoplasia type 2A, type 2B and familial medullary thyroid carcinoma syndrome].
Obara T; Yamashita T; Kanbe M; Ito Y; Egawa S; Yamaguchi K
Nihon Rinsho; 1995 Nov; 53(11):2708-15. PubMed ID: 8538031
[TBL] [Abstract][Full Text] [Related]
4. Clinical manifestations of familial medullary thyroid carcinoma.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):348-50. PubMed ID: 15271414
[TBL] [Abstract][Full Text] [Related]
5. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B.
Zhou Y; Zhao Y; Cui B; Gu L; Zhu S; Li J; Liu J; Yin M; Zhao T; Yin Z; Yu C; Chen C; Wang L; Xiao B; Hong J; Zhang Y; Tang Z; Wang S; Li X; Ning G
Clin Endocrinol (Oxf); 2007 Oct; 67(4):570-6. PubMed ID: 17573899
[TBL] [Abstract][Full Text] [Related]
6. A large family with hereditary MTC: role of RET genetic analysis in differential diagnosis between MEN 2A and FMTC.
Chiefari E; Chiarella R; Crocetti U; Tardio B; Arturi F; Russo D; Trischitta V; Filetti S; Zingrillo M
Horm Metab Res; 2001 Jan; 33(1):52-6. PubMed ID: 11280716
[TBL] [Abstract][Full Text] [Related]
7. Transcriptome analysis in mouse tumors induced by Ret-MEN2/FMTC mutations reveals subtype-specific role in survival and interference with immune surveillance.
Engelmann D; Koczan D; Ricken P; Rimpler U; Pahnke J; Li Z; Pützer BM
Endocr Relat Cancer; 2009 Mar; 16(1):211-24. PubMed ID: 18984779
[TBL] [Abstract][Full Text] [Related]
8. Genetic testing in multiple endocrine neoplasia and related syndromes.
Calender A
Forum (Genova); 1998; 8(2):146-59. PubMed ID: 9666051
[TBL] [Abstract][Full Text] [Related]
9. RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan.
Kameyama K; Okinaga H; Takami H
Biomed Pharmacother; 2004; 58(6-7):345-7. PubMed ID: 15271413
[TBL] [Abstract][Full Text] [Related]
10. [The RET gene in multiple endocrine neoplasia type 2 (MEN 2)].
Ito T; Shirahama S; Ogura K; Yamamoto S; Takami H
Nihon Rinsho; 2004 May; 62(5):883-8. PubMed ID: 15148813
[TBL] [Abstract][Full Text] [Related]
11. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
[TBL] [Abstract][Full Text] [Related]
12. Multiple endocrine neoplasia type 2.
Wohllk N; Schweizer H; Erlic Z; Schmid KW; Walz MK; Raue F; Neumann HP
Best Pract Res Clin Endocrinol Metab; 2010 Jun; 24(3):371-87. PubMed ID: 20833330
[TBL] [Abstract][Full Text] [Related]
13. [Predictive genetic investigations. Individualization of diagnosis and treatment in families with multiple endocrine neoplasia type II].
Engelbach M; Kunt T; Kann P; Manfras B; Hankeln T; Forst T; Pfützner A; Heerdt S; Walgenbach S; Lehnert H; Beyer J
Dtsch Med Wochenschr; 2000 Jan; 125(3):37-44. PubMed ID: 10681997
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics of multiple endocrine neoplasia].
Conte-Devolx B; Niccoli P;
Bull Acad Natl Med; 2010 Jan; 194(1):69-78; discussion 78-9. PubMed ID: 20669560
[TBL] [Abstract][Full Text] [Related]
15. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A.
Lips CJ; Landsvater RM; Höppener JW; Geerdink RA; Blijham G; van Veen JM; van Gils AP; de Wit MJ; Zewald RA; Berends MJ
N Engl J Med; 1994 Sep; 331(13):828-35. PubMed ID: 7915822
[TBL] [Abstract][Full Text] [Related]
16. A rapid screening method for the detection of mutations in the RET proto-oncogene in multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma families.
Marsh DJ; Robinson BG; Andrew S; Richardson AL; Pojer R; Schnitzler M; Mulligan LM; Hyland VJ
Genomics; 1994 Sep; 23(2):477-9. PubMed ID: 7835899
[TBL] [Abstract][Full Text] [Related]
17. Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
Frank-Raue K; Rondot S; Schulze E; Raue F
Clin Lab; 2007; 53(5-6):273-82. PubMed ID: 17605401
[TBL] [Abstract][Full Text] [Related]
18. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2).
Jimenez C; Gagel RF
Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S150-7. PubMed ID: 15135800
[TBL] [Abstract][Full Text] [Related]
19. Multiple endocrine neoplasia (MEN)--an overview and case report--patient with sporadic bilateral pheochromocytoma, hyperparathyroidism and marfanoid habitus.
Fassbender WJ; Krohn-Grimberghe B; Görtz B; Litzlbauer D; Stracke H; Raue F; Kaiser HE
Anticancer Res; 2000; 20(6C):4877-87. PubMed ID: 11205236
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
